Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma | NEJM
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update - ScienceDirect
The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort - Mustafa Karaağaç, Yasin Sezgin, Melek Karakurt Eryılmaz, Murat Araz, Muhammet Ali
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial - The Lancet Oncology
Frontiers | Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial - European Urology
Pazopanib (Votrient) | CancerIndex
ASCO 2019: Randomized, Double-Blind Phase III Study of Pazopanib versus Placebo in Patients with Metastatic Renal Cell Carcinoma who have no Evidence of Disease Following Metastasectomy - Medical Oncologist Perspective
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Overall survival in leiomyosarcoma patients. | Download Scientific Diagram
Overall survival with sunitinib or pazopanib for first-line treatment... | Download Scientific Diagram
![PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/343485ee055845a60e57da69b711a4ea3bb2d505/4-Figure2-1.png "PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar")
PDF] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial | Semantic Scholar
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma | BMC Cancer | Full Text
The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort - Mustafa Karaağaç, Yasin Sezgin, Melek Karakurt Eryılmaz, Murat Araz, Muhammet Ali
Progression free survival for patient with metastatic bone sarcoma... | Download Scientific Diagram
Clinical Trials | VOTRIENT® (pazopanib) tablets
JCM | Free Full-Text | Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas | British Journal of Cancer
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence | Signal Transduction and Targeted Therapy
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
Hopes and failures in front-line ovarian cancer therapy - ScienceDirect
Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective - Bae - 2022 - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma - Clinical Genitourinary Cancer
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
Full article: Pazopanib for the treatment of soft-tissue sarcoma
Biomedicines | Free Full-Text | Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
